<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118999</url>
  </required_header>
  <id_info>
    <org_study_id>16.18.BIO</org_study_id>
    <nct_id>NCT03118999</nct_id>
  </id_info>
  <brief_title>Plasma Level of Various Omega-3 Lipids</brief_title>
  <official_title>Plasma Level of Various Omega-3 Lipids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic properties of 3 OM3
      oils after a single-dose administration in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-24h) Plasma OM3</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Baseline-adjusted total plasma OM3 AUC(0-24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (AUC) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>AUC(0-24h) Plasma EPA and DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Cmax Plasma EPA and DHA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Tmax) for EPA and DHA</measure>
    <time_frame>From Time 0 hour to Time 24 hours</time_frame>
    <description>Tmax Plasma EPA and DHA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OM3 derivatives 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each sequence: OM3 derivatives 1 at Period 1 or Period 2 or Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM3 derivatives 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each sequence: OM3 derivatives 2 at Period 1 or Period 2 or Period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM3 derivatives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each sequence: OM3 derivatives 3 at Period 1 or Period 2 or Period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Period 1</intervention_name>
    <description>OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3</description>
    <arm_group_label>OM3 derivatives 1</arm_group_label>
    <arm_group_label>OM3 derivatives 2</arm_group_label>
    <arm_group_label>OM3 derivatives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Period 2</intervention_name>
    <description>OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3</description>
    <arm_group_label>OM3 derivatives 1</arm_group_label>
    <arm_group_label>OM3 derivatives 2</arm_group_label>
    <arm_group_label>OM3 derivatives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Period 3</intervention_name>
    <description>OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3</description>
    <arm_group_label>OM3 derivatives 1</arm_group_label>
    <arm_group_label>OM3 derivatives 2</arm_group_label>
    <arm_group_label>OM3 derivatives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 65 years old

          -  BMI in the normal and overweight range (18.5 to 29.9 kg/m2)

          -  Able to understand and to sign written informed consent prior to trial entry

          -  Informed consent signed

        Exclusion Criteria:

          -  Food allergy

          -  Documented clinically relevant disease impacting the endpoints of the study or the
             safety of the subject, as determined by the medical (screening) visit:

             i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease,
             etc. ii. Known hypertriglyceridemia (on anamnesis) iii. Known Type2 Diabetes Mellitus

          -  Under medication that may impact:

               1. Dietary fat absorption and metabolism like statins, bile acid sequestrants, lipid
                  lowering medications, or fibrates (to the opinion of the investigator)

               2. Coagulation (blood thinning medications, anticoagulants). Indeed, OM3 have been
                  shown to possibly exert some bleeding by themselves that may increase the
                  bleeding effects of aspirin and anticoagulants

          -  Having taken omega-3, EPA/DHA, fish oil supplementation for more than two consecutive
             weeks during the last 2 months

          -  Having given blood within the last month, or willing to make a blood donation until
             one month following the end of the study

          -  Subjects not willing and/or not able to comply with scheduled visits and with the
             requirements of the study protocol, including trial products consumption and food
             restriction

          -  Pregnancy (on anamnesis)

          -  Any direct collaborator of the study leader (Dr. Maurice Beaumont)

          -  Currently participating or having participated in another clinical trial during the
             last month prior to the beginning of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nestlé Research Center / Clinical Development Unit / Metabolic Unit</name>
      <address>
        <city>Lausanne 26</city>
        <state>Vaud</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Beaumont, MD, PhD</last_name>
      <phone>+41217858054</phone>
      <email>maurice.beaumont@rdls.nestle.com</email>
    </contact>
    <investigator>
      <last_name>Maurice Beaumont, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

